CD274 and non-small cell lung carcinoma: The role of PD-L1 as an effectively predictive biomarker largely based on the results of the KEYNOTE 024 trial study in non-small cell lung cancer, which showed superior outcomes in patients with PD-L1 expression greater than 50% treated with pembrolizumab as the first-line method (42).